Study of a new drug for advanced solid tumors with MTAP deletion
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a specific genetic change called an MTAP deletion.
- You must have already tried standard treatments or not be able to take them.
- You cannot have any stomach or bowel conditions that are active or happened in the last 3 months.
- You cannot have taken part in a study with a radioactive drug in the past year.
- You must be able to have blood and urine samples taken to measure how the study drug is processed in your body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
This trial tests a new drug, BMS-986504, in people with pancreatic cancer that has a specific genetic change called MTAP deletion. The study aims to see if this drug can help shrink or control the tumor.
This study tests an experimental oral medication (navlimetostat) for people with advanced lung cancer whose tumors have a specific genetic change called an MTAP deletion. It’s for those whose cancer has progressed after earlier treatments.
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
Hear when a new Advanced Solid Tumors With Homozygous MTAP Deletion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.